Combination of Diclofenac and Sublingual Nitrates Is Superior to Diclofenac Alone in Preventing Pancreatitis After Endoscopic Retrograde Cholangiopancreatography

Gastroenterology. 2019 May;156(6):1753-1760.e1. doi: 10.1053/j.gastro.2019.01.267. Epub 2019 Feb 14.

Abstract

Background & aims: Acute pancreatitis is a major adverse event of endoscopic retrograde cholangiopancreatography (ERCP). Rectal administration of nonsteroidal anti-inflammatory drugs (NSAIDs) decreases the incidence of post-ERCP pancreatitis (PEP). Little is known about the combined effects of sublingual nitrate and NSAIDs. We performed a randomized trial to assess whether the combination of NSAIDs and sublingual nitrate is more effective than NSAIDs alone in preventing PEP.

Methods: In a prospective superiority trial, eligible patients underwent ERCP at 12 endoscopic units in Japan, from March 2015 through May 2018. Patients were randomly assigned to groups given diclofenac suppositories (50 mg) within 15 minutes after the endoscopic procedure alone (diclofenac-alone group, n = 442) or in combination with sublingual isosorbide dinitrate (5 mg) 5 minutes before the endoscopic procedure (combination group, n = 444). The primary endpoint was the occurrence of PEP.

Results: PEP developed in 25 patients in the combination group (5.6%), and in 42 patients in the diclofenac-alone group (9.5%) (relative risk 0.59; 95% confidence interval 0.37-0.95; P = .03). Moderate to severe pancreatitis developed in 4 patients (0.9%) in the combination group, and 10 patients (2.3%) in the diclofenac-alone group (relative risk 0.12; 95% confidence interval 0.13-1.26; P = .12). There was no serious adverse event related to the additional administration of sublingual nitrate.

Conclusions: In a randomized controlled trial, we found that prophylaxis with rectal diclofenac and sublingual nitrate significantly reduces the overall incidence of PEP compared with diclofenac suppository alone. ClinicalTrials.gov, no: UMIN 000016274.

Keywords: Drug; Inflammation; Pancreas; Smooth-Muscle Relaxant.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Administration, Sublingual
  • Aged
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Cholangiopancreatography, Endoscopic Retrograde / adverse effects*
  • Diclofenac / therapeutic use*
  • Drug Therapy, Combination
  • Female
  • Humans
  • Isosorbide Dinitrate / administration & dosage
  • Isosorbide Dinitrate / therapeutic use*
  • Male
  • Middle Aged
  • Nitric Oxide Donors / administration & dosage
  • Nitric Oxide Donors / therapeutic use*
  • Pancreatitis / etiology
  • Pancreatitis / prevention & control*
  • Prospective Studies

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Nitric Oxide Donors
  • Diclofenac
  • Isosorbide Dinitrate

Associated data

  • UMIN-CTR/UMIN 000016274